2minutemedicine.com17h
Twice-yearly lenacapavir prevents HIV more effectively than daily F/TDF or F/TAF
In this randomized controlled trial, among adolescent girls and young women, it was found that twice-yearly lenacapavir ...
Gilead's HIV Prevention Treatment Lenacapavir Shows Potential
GILD's recent upbeat data on lenacapavir underscore the investigational drug???s potential to prevent HIV in the targeted ...
Managed Healthcare Executive1d
PrEP Overview in Light of Lenacapavir Licensing Agreements
Gilead Sciences’s decision to distribute HIV prevention drug lenacapavir made the news this month when they signed ...
BMJ1d
Lenacapavir: a giant step forward in HIV prevention—but a missed opportunity for achieving equity and access
This year has seen a double dose of optimism in the field of HIV prevention. First, on 20 June 2024, came the results of the Purpose-1 trial in South Africa and Uganda.1 This randomised controlled ...
The American Journal of Managed Care5d
Lenacapavir Highly Effective in Preventing HIV
New data from the PURPOSE 2 trial continue to show the efficacy of lenacapavir in HIV prevention in individuals who have sex ...
Gilead Agrees to Allow Generic Version of Groundbreaking H.I.V. Shot in Poor Countries
The drugmaker Gilead Sciences on Wednesday announced a plan to allow six generic pharmaceutical companies in Asia and North ...
unaids13d
UNAIDS response to Gilead’s announcement on signing voluntary licensing agreements on lenacapavir with six generic manufacturers
We welcome Gilead’s statement of commitment to non-profit pricing, but we had been waiting eagerly for a specific price. We ...
Dr Reddy's, Hetero ink royalty-free voluntary licencing pacts with Gilead Sciences for HIV drug Lenacapavir
Dr Reddy's Laboratories and Hetero, along with other generic drug makers, enter into voluntary licensing agreements with ...
Dr. Reddy’s and Hetero join hands with Gilead to broaden access to HIV drug Lenacapavir in low-income countries
Dr. Reddy’s and Hetero partner with Gilead Sciences to manufacture and distribute Lenacapavir for HIV treatment in LMICs.
Indian pharma firms ink deal with U.S. drug maker Gilead to make, market generic HIV drug lenacapavir
Dr. Reddy's, Hetero, and Mylan partner with Gilead Sciences to manufacture generic lenacapavir for HIV prevention globally.